Beam Therapeutics is trading at $32.36 (+9.09%) as shares rise following the presentation of positive updated BEAM-302 data at the European Respiratory Society (ERS) Congress on September 8, 2026. - Updated Phase 1/2 clinical data for BEAM-302 in alpha-1 antitrypsin deficiency (AATD) showed positive results, with mean steady-state total AAT levels exceeding the 11 µM protective threshold (e.g., 14.4 µM and 13.5 µM at 60 mg dose) and mutant Z-AAT reduced by 84%. - Beam Therapeutics has initiated dosing in a global pivotal cohort for BEAM-302 and plans to pursue a U.S. accelerated approval pathway. - The company is also hosting a webcast today, September 8, 2026, at 7:00 a.m. ET to review these updates.